홈 › 자궁내막암 › 오클라호마 › Oklahoma City
OK Oklahoma City의 자궁내막암 임상 시험
자궁내막암 관련 연구 25개가 Oklahoma City 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
피험자 모집 중1/2상
- University of Oklahoma, Oklahoma City
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
피험자 모집 중1상
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
피험자 모집 중1/2상
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
피험자 모집 중1/2상
- Stephenson Cancer Center, Oklahoma City
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
피험자 모집 중1/2상
- University of Oklahoma, Oklahoma City
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
피험자 모집 중3상
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
피험자 모집 중3상
- Research Site, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
피험자 모집 중1상
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
피험자 모집 중2상
- Stephenson Cancer Center at OU Health, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
피험자 모집 중1상
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
피험자 모집 중1/2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
피험자 모집 중1/2상
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- Stephenson Cancer Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
피험자 모집 중1/2상
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
피험자 모집 중관찰 연구
- Mercy Hospital - OKC, Oklahoma City
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
피험자 모집 중1/2상
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
Uterine Preservation Via Lifestyle Transformation
피험자 모집 중2상
- University of Oklahoma, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
피험자 모집 중1상
- Dren Investigational Site, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
피험자 모집 중1상
- University of Oklahoma, Oklahoma City
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
피험자 모집 중2상
- Oklahoma University Stephenson Cancer Center, Oklahoma City
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
피험자 모집 중2상
- University of Oklahoma, Oklahoma City
다른 도시의 자궁내막암 시험
- Houston, TX연구 68개
- New York City, NY연구 52개
- Boston, MA연구 50개
- Arlington, VA연구 39개
- Nashville, TN연구 38개
- Los Angeles, CA연구 34개
- St. Louis, MO연구 29개
- Philadelphia, PA연구 28개
- San Antonio, TX연구 27개
- Columbus, OH연구 25개
- Chicago, IL연구 25개
- Queens, NY연구 25개
Oklahoma City의 다른 연구
- 비소세포폐암연구 28개
- 난소암연구 28개
- 대장직장암연구 22개
- 전립선암연구 21개
- 폐암연구 19개
- 유방암연구 17개
- 전이성 암연구 16개
- 암 (전체)연구 14개
- 급성 골수성 백혈병연구 14개
- 두경부 편평세포암연구 13개
- 방광암연구 11개
- 췌장암연구 11개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.